Holen Sie sich die Stockscreener-App
5.95
0.67%
-0.04
Vorhandelsmarkt:
5.51
-0.44
-7.39%
Schlusskurs vom Vortag:
$5.99
Offen:
$5.97
24-Stunden-Volumen:
48,412
Relative Volume:
0.95
Marktkapitalisierung:
$26.84M
Einnahmen:
$85.53M
Nettoeinkommen (Verlust:
$-9.78M
KGV:
-2.7105
EPS:
-2.1952
Netto-Cashflow:
$1.28M
1W Leistung:
-1.49%
1M Leistung:
+13.33%
6M Leistung:
-15.00%
1J Leistung:
+16.85%
1-Tages-Spanne:
$5.78
$6.039
1-Wochen-Bereich:
$5.78
$6.69
52-Wochen-Spanne:
$3.755
$9.40
Harvard Bioscience Inc Stock (HBIO) Company Profile
Firmenname
Harvard Bioscience Inc
Sektor
Telefon
(508) 893-8999
Adresse
84 OCTOBER HILL RD, HOLLISTON, MA
Compare HBIO vs ISRG, BDX, ALC, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HBIO
Harvard Bioscience Inc
|
5.95 | 27.02M | 85.53M | -9.78M | 1.28M | -2.1952 |
ISRG
Intuitive Surgical Inc
|
417.07 | 147.53B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
145.16 | 40.10B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
65.84 | 32.33B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
37.09 | 31.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
193.94 | 27.96B | 5.54B | 1.52B | 1.74B | 10.37 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-09 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-03-10 | Hochstufung | The Benchmark Company | Speculative Buy → Buy |
| 2021-01-07 | Hochstufung | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-09 | Eingeleitet | Northland Capital | Outperform |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2019-07-08 | Herabstufung | Janney | Buy → Neutral |
| 2018-01-24 | Bestätigt | Janney | Buy |
| 2018-01-23 | Bestätigt | The Benchmark Company | Buy |
| 2016-11-17 | Eingeleitet | Singular Research | Buy |
| 2015-07-28 | Eingeleitet | The Benchmark Company | Buy |
Alle ansehen
Harvard Bioscience Inc Aktie (HBIO) Neueste Nachrichten
Director at Harvard Bioscience (HBIO) granted 16,556 restricted stock units - Stock Titan
HBIO Stock Price, Quote & Chart - ChartMill
Harvard Bioscience (HBIO) director awarded 16,556 restricted stock units - Stock Titan
Harvard Bioscience (NASDAQ: HBIO) awards director 16,556 RSUs - Stock Titan
Harvard Bioscience (HBIO) director awarded 16,556 RSUs in new grant - Stock Titan
Director at Harvard Bioscience (HBIO) awarded 16,556 RSUs - Stock Titan
Harvard Bioscience | 8-K: Harvard Bioscience Announces First Quarter 2026 Financial Results - Moomoo
Harvard Bioscience Shareholders Expand Equity Plans, Elect Directors - TipRanks
Harvard Bioscience (NASDAQ: HBIO) shareholders approve equity and ESPP share increases - Stock Titan
Harvard Bioscience (HBIO) price target increased by 200.00% to 6.12 - MSN
Earnings call transcript: Harvard Bioscience Q1 2026 misses EPS forecast, stock drops - Investing.com Nigeria
Harvard Bioscience: HBIO stock stalls, margin pressure in focus - Bez Kabli
HBIO PE Ratio & Valuation, Is HBIO Overvalued - Intellectia AI
HBIO Q1 2026 Earnings: EPS Surprises to the Upside Despite Challenging QuarterEstimate Dispersion - thelegaladvocate.com
Harvard Bioscience Slips as Traders Assess Support Levels; HBIO Down Nearly 3%Open Trading Community - Newser
Harvard Bioscience (HBIO) Q1 2026 Earnings Beat: Revenue $N/A, EPS $-0.33Real Trader Insights - Newser
Harvard Bioscience stock (US4169061052): Q2 2025 mixed results still define the story - AD HOC NEWS
Harvard Bioscience, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:HBIO) 2026-05-15 - Seeking Alpha
Earnings call transcript: Harvard Bioscience misses Q1 2026 forecasts - Investing.com UK
Earnings call transcript: Harvard Bioscience misses Q1 2026 forecasts By Investing.com - Investing.com Australia
Harvard Bioscience (HBIO) insider entity reports 293,676 shares, 6.5% stake - Stock Titan
Harvard Bioscience Transitions to Translational Science Focus in 2026 - HarianBasis.co
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q1 2026 Earnings Call Transcript - Insider Monkey
Harvard Bioscience Inc (HBIO) Q1 2026 Earnings Call Highlights: Revenue Growth Driven by New Product Innovations - GuruFocus
Harvard Bioscience Q1 2026 slides: margins rise amid revenue miss By Investing.com - Investing.com Nigeria
Harvard Bioscience Q1 2026 Earnings Call Transcript - MarketBeat
HBIO Maintains Positive Outlook for FY26 Financial Performance - GuruFocus
Harvard Bioscience (HBIO) Reports Q1 Earnings and Reaffirms 2026 Revenue Guidance - GuruFocus
Discontinued operations of Harvard Bioscience, Inc. – FWB:HBI0 - TradingView
Harvard Bioscience Reaffirms Full-Year 2026 Financial Guidance >HBIO - Moomoo
Harvard Bioscience: Consolidation of Manufacturing Operations Progressing on Schedule >HBIO - Moomoo
Harvard Bioscience (NASDAQ: HBIO) posts Q1 2026 loss as debt costs rise - Stock Titan
Harvard Bioscience, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
HBIO Forecasts Q2 Margins and Revenue Growth - GuruFocus
HBIO Sees Q1 Revenue at $20.8M, Positive Trends in Product Adoption - GuruFocus
Harvard Bioscience Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Harvard Bioscience reaffirms 2026 outlook for 2%-4% revenue growth as Project Viking targets $4M annual savings - MSN
Harvard Bioscience (HBIO) Q1: EPS Not Disclosed, Revenue $20.8M - GuruFocus
Harvard Bioscience Q1 2026 slides: margins rise amid revenue miss - Investing.com
Harvard Bioscience Still Sees 2026 Revenue Up 2%-4% >HBIO - Moomoo
Earnings call transcript: Harvard Bioscience Q1 2026 misses EPS forecast, stock drops By Investing.com - Investing.com South Africa
Harvard Bioscience Announces Q1 2026 Financial Results: $20.8M Revenue, 59% Gross Margin, Key SEC Filing Details 9 - Minichart
Harvard Bioscience Accelerates Growth with Human-Relevant Translational Tools, Leading Recurring Revenue and Innovation in Preclinical Research (May 2026) 10121415 - Minichart
Harvard Bioscience Still Sees 2026 Adjusted Ebitda Up 6%-10% >HBIO - Moomoo
Harvard Bioscience Inc (NASDAQ:HBIO) Q1 Results Show Revenue Miss Offsets Earnings Beat - ChartMill
Finanzdaten der Harvard Bioscience Inc-Aktie (HBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Harvard Bioscience Inc-Aktie (HBIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DENELSKY STEPHEN J | Director |
Mar 17 '26 |
Buy |
4.87 |
10,000 |
48,700 |
21,000 |
| Snider William | Director |
Mar 16 '26 |
Buy |
4.99 |
12,525 |
62,500 |
23,525 |
| Snider William | Director |
Mar 17 '26 |
Buy |
4.85 |
8,475 |
41,104 |
32,000 |
| Duke John D | Chief Executive Officer |
Mar 16 '26 |
Buy |
5.01 |
5,000 |
25,050 |
105,000 |
1.68%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):